Pseudomonas aeruginosa is a virulent pathogen in immunocompromised patients, particularly neutropenic patients (22, 25) . Nosocomial pneumonias caused by P. aeruginosa are associated with especially high mortality, despite recent advances in antimicrobial chemotherapy (4, 12) . Passive immunotherapy with monoclonal antibodies (MAbs) reactive with surface-exposed antigens of P. aeruginosa has been evaluated as a means of improving the outcome from Pseudomonas infections (24, 31, 32) . Only MAbs specific for the 0 side chain of lipopolysaccharide (LPS) have been reported to be protective in normal animal models of P. aeruginosa pneumonia (21, 23) . However, a significant disadvantage of these LPS-reactive MAbs is the necessity to develop a MAb cocktail consisting of several MAbs to provide protection against P. aeruginosa strains with a variety of LPS serotypes (13) .
The flagella of P. aeruginosa possess one of two major antigenic types, and more than 98% of clinical P. aeruginosa isolates are flagellated (3, 28) . The importance of motility as a virulence determinant of P. aeruginosa is suggested by previous experiments in burn wound models (8, 15) . Recent studies have demonstrated the protective effects of divalent flagella antigens or antiflagella antiserum from fatal P. aeruginosa infections in the same model (7, 9) . Moreover, murine and human antiflagella MAbs also strongly protect burned mice from P. aeruginosa infections (18, 28, 29) . Yet, there is * Corresponding author. no evidence that antiflagella MAbs are protective in animal models of P. aeruginosa pneumonia.
Sparfloxacin (AT-4140) is a newly developed quinolone antibiotic for oral use that has broad antibacterial activity (17) , excellent tissue penetration, and long half-lives in plasma and tissue (16) . Sparfloxacin acts synergistically with a murine LPS-specific MAb against Pseudomonas pneumonia in neutropenic mice (20) . The present study was designed to compare the protective activity of a human anti-flagella MAb with that of human anti-LPS MAb in a neutropenic mouse model of P. aeruginosa pneumonia and to examine the antibacterial interaction between the antiflagella MAb and sparfloxacin in this model.
MATERIALS AND METHODS
Reagents. Cyclophosphamide was provided by Shionogi & Co., Ltd., Osaka, Japan. Sparfloxacin, a newly developed quinolone with potent antibacterial activity, was provided in powder form by Dainippon Pharmaceutical Co., Ltd., Osaka, Japan. Prior to use, sparfloxacin was suspended in 0.5% tragacanth gum (Nacalai Tesque, Inc., Tokyo, Japan) for oral administration.
Bacteria. P. aeruginosa G348 with type a flagella and Fisher immunotype 2 (It-2) LPS was originally obtained from the Oncogen Infectious Disease Therapeutics Biological Resources Bank (Bristol-Myers Squibb, Seattle, Wash.). This organism was grown overnight on brain heart infusion agar (Difco, Detroit, Mich.) at 37°C, harvested in sterile saline, resuspended in brain heart infusion broth (Difco) containing 2% skim milk, and stored at -80°C until use. The MIC of sparfloxacin was determined to be 1.56 ,ug/ml by the agar dilution method in Mueller-Hinton medium.
Generation and characterization of MAbs. Human anti-P.
aenuginosa flagella MAbs 21B8 (anti-type a flagella) and 2B8
(anti-type b flagella) and human anti-P. aeruginosa Fisher It-2 LPS MAb 2H9 was generated by cell-driven EpsteinBarr virus transformation of peripheral blood B cells from healthy individuals or patients with cystic fibrosis (30) . Transformed cells producing antiflagella or anti-LPS antibody were identified by an enzyme-linked immunosorbent assay (ELISA) by using P. aeruginosa strains of known flagella or LPS type (28) . Following enrichment by lowdensity cell culture, specific antibody-producing cells were fused with the murine myeloma X63-Ag8.653 (33) and antiflagella or anti-LPS MAb, producing heterohybrid cells cloned by a single cell culture. The specificity of each MAb for type a flagella, type b flagella, or It-2 LPS was confirmed by a combination of indirect immunofluorescence on whole bacteria with a known LPS type and by immunoblot analysis with purified flagella and LPS preparations (28) . MAbs 21B8, 2B8, and 2H9 were each determined to belong to the immunoglobulin Gl (IgGl) subclass by capture ELISA by using MAb to human IgG subclass (Calbiochem Corp., San Diego, Calif.). Purified MAbs were prepared by growth of the respective hybrids in serum-free media (HB 101; Irvine Scientific, Santa Ana, Calif.); this was followed by concentration of the spent supernatant with a Pellicon apparatus (Millipore, Bedford, Mass.) and then purification by the standard protein A affinity chromatography method. After extensive dialysis against phosphate-buffered saline (PBS), the MAbs were diluted in PBS to a concentration of 5 to 10 mg/ml and were then frozen at -70°C until use. Typing of flagella. A slide coagglutination assay was performed on 95 P. aeruginosa clinical isolates from patients with lower respiratory tract infections by the following modified procedures (3). All strains were collected from the clinic of the Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, and its affiliated hospitals located near Nagasaki, Japan. A total of 20 pl of each of antiflagella MAb (MAbs 21B8 and 2B8) solution at 20 ,ug/ml and 10 RI of 0.7% (vol/vol) formalin-treated Staphylococcus aureus bearing protein A (Zysorbin; Zymed, San Francisco, Calif.) were mixed, and then the mixture was combined with 10 ,u of a bacterial suspension at a concentration of approximately 109 CFU on a glass slide. The glass slide was rocked on a reeling apparatus until visible agglutination developed or for a maximum of 10 min, when the reaction was deemed negative if there was no visible agglutination.
Experimental pneumonia in neutropenic mice. A neutropenic murine model ofP. aeruginosa pneumonia was used as described previously (20) . Five-week-old specific-pathogenfree female Slc:ICR mice were obtained from Shizuoka Agricultural Cooperation Associations for Laboratory Animals, Shizuoka, Japan. Animals were housed under clean conditions and were given sterile food and water. Neutropenia was produced by the subcutaneous injection of cyclophosphamide at a dose of 200 mg/kg of body weight once every other day for 2 days. On the fourth day after the first dose of cyclophosphamide, the total peripheral blood leukocyte count of treated mice was <10% of the pretreatment level. No neutrophils were detected in the blood of treated mice from days 4 to 6 after the first dose of cyclophosphamide. Four days after the first dose of cyclophosphamide, P. aeruginosa pneumonia was produced in neutropenic mice by intratracheal challenge with P. aeruginosa G348. Infected mice were monitored for 7 days after challenge. Preliminary challenge experiments with graded bacterial inocula provided a 50% lethal dose in this model. The 50% lethal dose was calculated to be 1.7 x 102 CFU by probit analysis. Quantitative bacterial cultures were performed at the indicated times after euthanization of the mice with ether. Lungs were removed aseptically and were homogenized in 9 ml of sterile saline per g of lung tissue prior to culture. Bronchoalveolar lavage was performed as described previously (20) . More than 97% of the cells in the lavage fluid from neutropenic mice 12 h after challenge were found to be alveolar macrophages (AMs).
The protective activity of MAb alone was compared among four groups of mice that each received MAbs 21B8, 2B8, or 2H9 or no treatment. The four groups of mice were made up of neutropenic mice challenged with P. aeruginosa G348 at a dose of 104 and 105 CFU per mouse. In preliminary experiments, we found no protective effect of MAb 21B8 or MAb 2H9 at doses of 1, 10, and 100 ,ug per mouse on the survival rates of mice challenged with P. aeruginosa G348 at 104 CFU per mouse. Therefore, 0.2 ml of approximately diluted MAbs at a dose of 500 p,g was given intravenously 2 h before bacterial challenge. Combination therapy with MAb 21B8 and sparfloxacin was evaluated in neutropenic mice challenged with P. aeruginosa G348 at a dose of 104 CFU per mouse. This experiment of combination therapy involved four groups of mice that each received no treatment (n = 21), MAb 21B8 alone (n = 16), sparfloxacin alone (n = 16), or both MAb 21B8 and sparfloxacin (n = 17). A total of 0.2 ml of MAb 21B8 at a dose of 500 ,ug was administered intravenously 12 h after bacterial challenge. Oral administration of sparfloxacin suspended in 0.5% tragacanth gum was initiated 12 h after challenge by using a sterile cannula and was continued every 12 h for 3 days (total of six doses). In a preliminary study, the 50% protective dose of sparfloxacin in this pneumonia model was determined to be 115 jig per mouse (4.6 mg/kg). Therefore, a dose of 62.5 jig per mouse (2.5 mg/kg) was chosen as a suboptimal dose of sparfloxacin.
Data on mouse survival in two experiments were pooled.
Motility inhibition assay. Inhibition of bacterial motility by MAbs was assayed as described previously (18) . In brief, 50 ,ul of a bacterial suspension at a cell density of 108 CFU/ml and 50 ,ul of MAb solution in sterile saline were incubated at room temperature for 15 min. Each 10 ,ul of the mixture was stabbed into the soft agar plates containing 1% tryptone, 0.3% yeast extract, 0.5% NaCl, and 0.3% agar. The diameters of bacterial swarms with sharp rings were measured after incubation at 37°C for 24 h. To assess the effect of sub-MICs of sparfloxacin on the inhibitory activity of MAb 21B8, sparfloxacin (final concentration, <0.1 ,ug/ml = 1/16 the MIC) was dissolved in the soft agar. The experiments were done in triplicate. Sparfloxacin at concentrations of 0.0125, 0.025, 0.05, and 0.1 1g/ml was not bactericidal for P. aeruginosa G348 at 3, 6 , and 24 h after the initiation of incubation by a previously published method (10 ers by bronchoalveolar lavage and were prepared as described previously (26) . AMs were suspended in GHBSS2+ at a concentration of 2.5 x 106/ml and contained less than 5% polymorphonuclear leukocytes. Fresh absorbed normal human serum (AbsNHS) was prepared by a previously published method by using live homologous bacteria (19) . AbsNHS (1%) was used as a complement source because of the low levels of complement in bronchial secretions (27 (Fig. 2) . At 30 h postchallenge with 104 CFU of strain G348, the bacterial density reached approximately 4 x 108 CFU/g of lung tissue, and bacteremia was seen in untreated mice at this time (Fig. 3) . Intravenous administration of MAb 21B8 (21B8, 2B8, or 2H9) at a dose of 500 ,ug per mouse or saline was administered intravenously to five or six mice per group 2 h before challenge. Mice were challenged intratracheally with 104 CFU of P. aeruginosa G348. *, P < 0.05; **, P < 0.01. at a dose of 500 ,ug at 12 h after challenge caused a significant decrease in bacterial numbers in blood (P < 0.01) but not lung tissue compared with the bacterial numbers in the untreated group. Treatment with sparfloxacin (62.5 ,ug) alone provided a significant reduction in the bacterial density in lung tissue and blood compared with that in the untreated group (P < 0.01). Combination therapy with MAb 21B8 and sparfloxacin exerted the greatest killing of bacteria in lung tissue and blood. The reduction in the bacterial number in the lung tissue of mice that received MAb 21B8 and sparLung 10 -9. Opsonophagocytic killing assays. Minimal killing of P.
aeruginosa G348 presensitized with MAb 21B8 was observed in the presence or absence of complement. Moderate killing of bacteria presensitized with MAb 2H9 was demonstrated in the presence but not the absence of complement (Fig. 4) . In contrast, an increase in the number bacteria pretreated with MAb 2B8 was seen in the presence or absence of complement.
Motility inhibition assay. MAb 21B8 produced a marked, dose-dependent inhibition of bacterial motility, while MAbs 2B8 and 2H9 showed no inhibitory activity (Fig. 5A) . The effect of sub-MICs (0.0125 to 0.1 ,ug/ml) of sparfloxacin on MAb 21B8-mediated inhibition of bacterial motility was examined (Fig. SB) . Sub-MICs of sparfloxacin inhibited bacterial motility in a dose-dependent manner. The addition of sparfloxacin also enhanced MAb 21B8-mediated inhibition of bacterial motility in a dose-dependent manner.
DISCUSSION
It was documented in the present study that a human IgG MAb reactive with type a flagella of P. aeruginosa afforded protection against fatal Pseudomonas lower respiratory tract infections caused by a homologous flagella type strain in neutropenic mice. The protective activity exhibited by antiflagella MAb in this model was comparable to that demonstrated by a human LPS-specific MAb with the same IgGl isotype. However, the dose of antiflagella MAb required for protection in this pneumonia model was quite high compared with the submicrogram protective doses exhibited by other antiflagella MAbs in a mouse burn sepsis model (18, 28, 29) . A human IgM antiflagella MAb at dose of 0.1 to 1.0 ,g per mouse, administered 1 h after infection, provided significant protection (18) . Administration of human and murine IgG antiflagella MAbs 1 h postchallenge also saved mice when as little as 1 to 2 ,ug per mouse was used (28, 29) . A similarly high dose of anti-LPS MAb was previously required for protection in the neutropenic pneumonia model (20) , suggesting the relative stringency of the model as far as antibody-mediated protection is concerned.
Both antiflagella and anti-LPS MAbs inhibited bacterial growth in lung tissues and limited bacterial spread to the bloodstreams of infected mice. The in vivo effects of antiflagella MAb may be related more to its inhibitory effect on bacterial motility than to its opsonic activity, which was demonstrated in the present AM-based in vitro assay. Two previous reports have described the opsonophagocytic activities of antiflagella antibodies in conjunction with polymorphonuclear leukocytes (1, 2) . Anderson and Montie (1, 2) demonstrated that this activity is complement independent (1) and that only 20% of internalized bacteria are killed when bacteria are opsonized with antiflagella antiserum (2) . Those Recent reports have demonstrated additive effects of a murine LPS-reactive MAb administered in combination with oral quinolone derivatives in neutropenic animal models of Pseudomonas infections (5, 6, 20) . In the present study, antiflagella MAb interacted additively with the quinolone antibiotic sparfloxacin, as reflected by the enhanced antibacterial activity in infected lung tissue and reduced mortality.
The reduced bacterial numbers in the lung tissues resulting from combination therapy with antiflagella MAb and sparfloxacin may partly be explained by the additive effects between antiflagella MAb and the sub-MIC of sparfloxacin on the inhibition of bacterial motility in soft agar plates. A possible explanation for the mechanism of this inhibitory effect is that sparfloxacin used at a nonbactericidal level might impede the function of flagella so that bacterial motility would be more efficiently inhibited by an antiflagella (14) . In contrast, in the present study, MAbs reactive with type a (MAb 21B8) and type b (MAb 2B8) flagella agglutinated 48. 4 and 44.2% of P. aeruginosa sputum isolates, respectively, suggesting broad therapeutic coverage by these two MAbs of respiratory isolates from patients without cystic fibrosis.
The data presented here emphasize the therapeutic potential of antiflagella MAbs in Pseudomonas lower respiratory tract infections in neutropenic hosts and the possibility of a therapeutic interaction between such MAbs and conventional antibiotics in the clinical setting.
